Telaprevir: New possibilities for antiviral treatment in patients with chronic hepatitis C

Cite item

Full Text


The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). The given data on Phase II and III clinical trials enable the authors to state the high efficacy of the drug in patients infected with hepatitis C virus type 1. The paper also provides data on the resistance of telaprevir and its drug interaction and denotes the place of the drug in the current antiviral treatment of patients with CHC.

Full Text

Телапревир: новые возможности противовирусного лечения больных хроническим гепатитом С. - Аннотация. В обзоре рассматриваются химическая структура, фармакодинамика и фармакокинетика телапревира - нового препарата прямого противовирусного действия - для лечения больных хроническим гепатитом С (ХГС). Представленные данные по клиническим исследованиям II и III фазы позволяют констатировать высокую эффективность препарата у пациентов с ХГС, инфицированных вирусом гепатита С 1-го типа. В статье представлены также данные о резистентности и межлекарственном взаимодействии телапревира, обозначено его место в современном противовирусном лечении больных с ХГС.


  1. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526.
  2. Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals. Index of questions. (accessed 2010 Oct 17)
  3. Barnes E. The need for HCV vaccine. WHO factsheet 2010. (accessed 2010 Dec.15)
  4. Incivek (telaprevir) package insert. Cambridge, MA: Vertex Pharmaceuticals Inc., 2011.
  5. Perni R.B., Almquist S., Byrn R.A. et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailabble inhibitor of hepatitis C virus NS3/4A serine protease. Antimicrob Agents Chemotherap 2006; 50: 899-909.
  6. Forestier N., Reesnik H.W., Weegnik C. et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 40-48.
  7. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in ILB28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  8. Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-802.
  9. Fellay J., Thompson AJ., Ge D. et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
  10. Thompson A.J., Fellay J., Patel K. et al. Variants in the ITPA gene protect against ribavirin-induced anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139: 1181-1189.
  11. Ochi H., Maekawi T., Abe H. et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-1197.
  12. Lawitz E., Rodriguez-Torres M., Muir A. et al. Antiviral effects and safety of telaprevir, peginterferon - alfa2a and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163-169.
  13. McHutchison Jg., Everson G.T., Gordon S.C. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
  14. Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  15. McHutchison J.G., Manns M.P., Muir A.J. et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
  16. Jacobson I.M., McHutchison Jg., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  17. Sherman K.E., Flamm S.L., Afdhal N.H. et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment - naïve genotype 1 HCV patients who achived an extended rapid viral response: final results of phase 3 ILLUMINATE study (abstract LB-2). Presented at 61st Annual Meeting of the American Association for the study of Liver Diseases. Boston, MA 2010.
  18. Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  19. Seden K., Back D., Khoo S. et al. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010; 65: 1079-1085.
  20. Kempf D., Klein C., Chen H.B. et al. Pharmacokinetic enhancement of the hhepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163-167.
  21. Garg V., van Heeswijk R., Lee J.E. et al. The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
  22. Sarrazin C., Kiefer T.L., Bartels D. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
  23. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
  24. Kuntzen T., Timm J., Berical A. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008; 48: 1769-1778.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies